Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors

This publication has 30 references indexed in Scilit:

• Efficacy of an Adeno-associated Virus 8-Pseudotyped Vector in Glycogen Storage Disease Type II
  Molecular Therapy, 2005
• Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6
  Molecular Therapy, 2004
• Immune Responses to Recombinant Adeno-Associated Virus Vectors: Putting Preclinical Findings into Perspective
  Human Gene Therapy, 2004
• Robust Adenoviral and Adeno-Associated Viral Gene Transfer to the In Vivo Murine Heart
  Circulation, 2003
• Phase I Trial of Intranasal and Endobronchial Administration of a Recombinant Adeno-Associated Virus Serotype 2 (rAAV2)-CFTR Vector in Adult Cystic Fibrosis Patients: A Two-Part Clinical Study
  Human Gene Therapy, 2003
• Packaging of an AAV vector encoding human acid α-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector
  Molecular Therapy, 2003
• Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1
  Journal of Virology, 2003
• Improved Hepatic Gene Transfer by Using an Adeno-Associated Virus Serotype 5 Vector
  Journal of Virology, 2002
• Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency
  Gene Therapy, 2002
• Sustained and Complete Phenotype Correction of Hemophilia B Mice Following Intramuscular Injection of AAV1 Serotype Vectors
  Molecular Therapy, 2001